Biomarker Testing Services Market Size & Growth Forecast 2027–2036, By Segments (Service, Application, End Use, Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Biomarker Testing Services Market size was more than USD 756.5 million in 2026 and is set to grow at a 8.65% CAGR between 2027 and 2036, surpassing USD 1.73 billion by 2036. The industry revenue for 2027 is estimated at USD 811.57 million.
Get more details on this report
Request Free Sample ReportBiomarker Testing Services Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 49.00% market share in 2026, supported by advanced clinical testing infrastructure, integrated healthcare networks, and consistent demand from precision medicine and drug development programs.
- Asia Pacific is expected to grow at a 9.83% CAGR as expanding diagnostic capacity, personalized medicine adoption, and increasing pharmaceutical research drive demand for specialized testing services.
Segment Momentum
- Oncology accounted for a 53.95% share in 2026 due to extensive biomarker use in cancer detection, patient stratification, treatment selection, and disease monitoring across clinical practice and research.
- Drug Discovery & Development is growing rapidly as biomarker testing is increasingly integrated earlier in development workflows to improve candidate selection, identify responsive populations, and measure treatment effects.
Market Expansion Drivers
- Growing demand for personalized medicine accelerating biomarker testing adoption in clinical research.
- Rising oncology prevalence increasing need for predictive and diagnostic biomarker analysis services.
- Pharmaceutical outsourcing of biomarker validation improving drug development efficiency and regulatory approvals.
Leading Market Participants
- Leading companies in the biomarker testing services market include IQVIA Holdings Inc. (United States), Thermo Fisher Scientific Inc. (United States), Charles River Laboratories International, Inc. (United States), Laboratory Corporation of America Holdings (United States), ICON plc (Ireland), Eurofins Scientific SE (Luxembourg), SGS S.A. (Switzerland), Syneos Health, Inc. (United States), Intertek Group plc (United Kingdom), BioAgilytix Labs, LLC (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 756.5 million
- 2027 Estimated Market Size: USD 811.57 million.
- Projected Market Size: USD 1.73 billion by 2036
- Growth Forecast: 8.65% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Biomarker Assay Development & Validation (Service) | Oncology (Application) | Pharmaceutical & Biotechnology Companies (End Use) | Molecular Biomarkers (Type)
- Emerging Opportunity Segment: Flow Cytometry (Service) | Drug Discovery & Development (Application) | CROs (End Use) | Cellular Biomarkers (Type)
Market Growth Drivers and Industry Trends
Growing demand for personalized medicine accelerating biomarker testing adoption in clinical research
The growing emphasis on individualized treatment approaches is driving the biomarker testing services market as researchers increasingly rely on biomarkers to identify patient subgroups and understand differences in disease biology and treatment response. Biomarker testing supports clinical research by helping investigators evaluate disease characteristics, identify suitable participants, assess therapeutic response, and monitor changes during treatment. The development of targeted therapies has further increased the importance of reliable biomarker analysis because treatment strategies often depend on identifying specific molecular or biological characteristics within patient populations. Advances in molecular diagnostics, genomic analysis, and other testing technologies are expanding the range of biomarkers that can be evaluated, while pharmaceutical and biotechnology researchers increasingly incorporate biomarker strategies into clinical development programs.
Rising oncology prevalence increasing need for predictive and diagnostic biomarker analysis services
Rising cancer incidence is increasing the requirement for sophisticated biomarker analysis, particularly as oncology treatment becomes more dependent on understanding tumor characteristics and patient-specific disease profiles. Within the biomarker testing services market, diagnostic and predictive biomarkers are used to support disease characterization, identify patients who may benefit from specific therapies, and evaluate potential treatment responses. Biomarker analysis can also help researchers investigate mechanisms of disease progression and treatment resistance, supporting the development of more targeted therapeutic strategies. The growing complexity of cancer biology and the expanding use of precision oncology are encouraging clinical researchers and drug developers to incorporate molecular and genetic testing into research programs, creating demand for specialized laboratory capabilities and analytical expertise.
Pharmaceutical outsourcing of biomarker validation improving drug development efficiency and regulatory approvals
Pharmaceutical companies are increasingly outsourcing specialized biomarker validation activities to external testing providers to access advanced laboratory capabilities, technical expertise, and established analytical workflows without building all resources internally. This trend will boost the biomarker testing services market demand as drug developers seek to streamline clinical development and generate reliable evidence for biomarker-based patient selection and treatment assessment. External service providers can support activities ranging from assay development and validation to sample analysis and interpretation, helping pharmaceutical organizations manage complex testing requirements across clinical programs. Outsourcing also enables development teams to focus internal resources on core drug development activities while obtaining standardized and reproducible biomarker data needed to support clinical decision-making and regulatory submissions.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Growing demand for personalized medicine accelerating biomarker testing adoption in clinical research | 2.00% | High | North America, Europe | High | Near Term |
| Rising oncology prevalence increasing need for predictive and diagnostic biomarker analysis services | 1.80% | High | North America, Asia Pacific | High | Mid Term |
| Pharmaceutical outsourcing of biomarker validation improving drug development efficiency and regulatory approvals | 1.50% | High | Europe, North America | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
The biomarker testing services market was led by North America, which accounted for a 49.00% share in 2026, reflecting the region's advanced clinical research ecosystem, strong pharmaceutical development activity, and established infrastructure for precision medicine. Increasing use of biomarkers for patient stratification, disease diagnosis, treatment selection, and clinical trial development is supporting demand for specialized testing capabilities. Well-developed laboratory networks and growing emphasis on personalized healthcare further reinforce the region's established position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is experiencing the fastest growth as healthcare systems expand their molecular diagnostics capabilities and pharmaceutical research activity increasingly incorporates biomarker-based approaches. Improvements in clinical research infrastructure, rising healthcare investment, and growing awareness of precision medicine are creating broader demand for testing services across oncology and other complex disease areas.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Validation FocusGermany emphasizes biomarker testing services supported by robust clinical validation and standardized laboratory practices. Healthcare institutions in Germany are strengthening collaborations with diagnostic providers to improve testing quality and support personalized therapeutic approaches.
France 🇫🇷
Personalized Care SupportFrance continues to strengthen biomarker testing services through broader integration into personalized treatment pathways. Healthcare organizations in France are increasing access to molecular diagnostics while improving coordination between laboratories, clinicians, and pharmaceutical stakeholders.
Italy 🇮🇹
Hospital Laboratory ModernizationItaly is modernizing biomarker testing services by expanding advanced diagnostic capabilities within hospital laboratory networks. Clinical laboratories in Italy are adopting standardized molecular testing processes that improve diagnostic consistency and support personalized patient management.
Japan 🇯🇵
Companion Diagnostics IntegrationJapan is expanding biomarker testing services alongside the increasing use of companion diagnostics in clinical care. Laboratories in Japan are prioritizing highly accurate molecular testing platforms that support treatment selection and improve diagnostic efficiency across specialized healthcare settings.
South Korea 🇰🇷
Advanced Genomic ServicesSouth Korea is investing in biomarker testing services that integrate genomic technologies into routine clinical workflows. Diagnostic providers in South Korea are enhancing laboratory capabilities to deliver faster and more comprehensive biomarker analysis for precision healthcare applications.
United States 🇺🇸
Precision Medicine ExpansionThe U.S. biomarker testing services market is advancing through broader adoption of precision medicine across oncology, immunology, and rare diseases. Clinical laboratories and healthcare providers in the U.S. are expanding molecular testing capabilities to support targeted therapies and personalized treatment decisions.
Segment Leadership and Growth Trends
Biomarker Testing Services Market Share (%), by Service, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportService Segment Analysis: Biomarker Assay Development & Validation (Largest Segment) vs Flow Cytometry (Fastest-Growing Segment)
Biomarker assay development & validation held the largest share of the biomarker testing services market in 2026, accounting for 48.52% share, driven by the essential role of validated assays in generating reliable and reproducible biomarker data. Pharmaceutical and research organizations require robust assay development to identify, quantify, and evaluate biomarkers throughout diagnostic research and therapeutic development workflows. Validation helps ensure that testing methods meet required standards for accuracy, consistency, sensitivity, and analytical performance. Increasing reliance on biomarker-driven research and precision medicine is therefore sustaining demand for specialized assay development and validation services.
Flow cytometry is emerging as the fastest-growing service segment as researchers increasingly require detailed characterization of cell populations and their biological properties. The technology enables simultaneous analysis of multiple cellular markers, making it valuable for immunology, oncology, drug development, and broader translational research. Its ability to generate detailed cellular profiles supports increasingly sophisticated biomarker studies and helps researchers evaluate treatment responses and disease mechanisms. Growing demand for high-content cellular analysis and multiparametric testing is strengthening the adoption of flow cytometry services across biomedical research workflows.
Application Segment Analysis: Oncology (Largest Segment) vs Drug Discovery & Development (Fastest-Growing Segment)
Oncology dominated the application landscape of the biomarker testing services market in 2026, representing 53.95% share, as biomarker analysis has become increasingly important for understanding tumor biology, identifying molecular characteristics, and supporting treatment selection. Biomarker testing assists researchers and clinicians in evaluating disease pathways and distinguishing patient populations that may respond differently to specific therapeutic approaches. The expanding focus on precision oncology is increasing the need for reliable molecular and cellular testing capabilities throughout cancer research and treatment development. This strong integration of biomarker analysis into oncology workflows supports the segment’s leading position.
Drug discovery & development is experiencing faster growth as pharmaceutical research increasingly incorporates biomarkers throughout the development process. Biomarkers can support target identification, mechanism-of-action studies, patient stratification, treatment-response evaluation, and safety assessment, helping researchers make more informed development decisions. Their integration into development workflows can improve the understanding of therapeutic effects and facilitate more targeted research strategies. As drug development becomes increasingly data-driven and precision-oriented, demand for specialized biomarker testing services is expanding across discovery and development activities.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Service | Biomarker Assay Development & Validation, Flow Cytometry, Others | Biomarker Assay Development & Validation | Flow Cytometry |
| Application | Oncology, Drug Discovery & Development, Others | Oncology | Drug Discovery & Development |
| End Use | Pharmaceutical & Biotechnology Companies, Research Institutes, CROs | Pharmaceutical & Biotechnology Companies | CROs |
| Type | Molecular Biomarkers, Cellular Biomarkers | Molecular Biomarkers | Cellular Biomarkers |
Competitive Landscape and Market Positioning
Major players in the biomarker testing services market:
1. IQVIA Holdings Inc. (United States)
2. Thermo Fisher Scientific Inc. (United States)
3. Charles River Laboratories International Inc. (United States)
4. Laboratory Corporation of America Holdings (United States)
5. ICON plc (Ireland)
6. Eurofins Scientific SE (Luxembourg)
7. SGS S.A. (Switzerland)
8. Syneos Health Inc. (United States)
9. Intertek Group plc (United Kingdom)
10. BioAgilytix Labs LLC (United States)
The biomarker testing services market is expanding due to increasing demand for precision diagnostics and targeted treatment approaches. Companies are investing heavily in advanced molecular testing technologies, companion diagnostics, and biomarker discovery research to improve clinical outcomes. Regulatory focus on personalized medicine and early disease detection is also accelerating innovation and service expansion across the market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| IQVIA Holdings Inc. (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Charles River Laboratories International Inc. (United States) | |||||||
| Laboratory Corporation of America Holdings (United States) | |||||||
| ICON plc (Ireland) | |||||||
| Eurofins Scientific SE (Luxembourg) | |||||||
| SGS S.A. (Switzerland) | |||||||
| Syneos Health Inc. (United States) | |||||||
| Intertek Group plc (United Kingdom) | |||||||
| BioAgilytix Labs LLC (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Thermo Fisher Scientific Inc. | Jun-24 | Thermo Fisher Scientific expanded its clinical research laboratory in Wisconsin, increasing its operational footprint to support emerging therapeutic areas. This facility expansion enhances the company's capacity for specialized biomarker testing and clinical development support, strengthening its position in the high-growth segments of precision medicine and advanced molecular diagnostics. |
| Labcorp | Apr-24 | Labcorp expanded its precision oncology portfolio, introducing advanced testing capabilities designed to accelerate drug development programs for biopharma and clinical research partners. This strategic broadening of services supports the increasing industry demand for biomarker-driven trial design, positioning Labcorp to better serve the complex analytical requirements of pharmaceutical companies focused on targeted oncological therapies. |
| Labcorp | Mar-24 | Labcorp launched a blood-based biomarker test for pTau217 to streamline Alzheimer's disease diagnosis and improve clinical trial patient selection. By integrating this high-specificity test into its diagnostic suite, Labcorp enhances its neurodegenerative disease capabilities and provides researchers with a more scalable tool for monitoring disease progression and assessing treatment efficacy in neurological drug development. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Biomarker Testing Services Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sample Type | Blood & Plasma, Tissue, Urine, Saliva, Other Biological Samples |
| Technology Platform | PCR & qPCR, Next-Generation Sequencing, Mass Spectrometry, Immunoassays, Flow Cytometry, Other Technologies |
| Delivery Model | In-House Testing, Outsourced Testing, Hybrid Testing |
Biomarker Testing Services Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Companion Diagnostics Commercial Opportunity Assessment |
|
| Precision Medicine Adoption by Clinical Specialty |
|
| Pharmaceutical Biomarker Outsourcing Strategy Benchmark |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of biomarker testing services?
What is the projected value of the biomarker testing services industry by 2036?
How is personalized medicine accelerating demand for biomarker testing services?
Why are pharmaceutical companies expanding outsourcing of biomarker validation activities?
Why does Oncology lead the biomarker testing services market?
Why is Drug Discovery & Development the fastest-growing application segment in the biomarker testing services market?
Why is North America the leading region for biomarker testing services?
What is fueling biomarker testing services market growth in Asia Pacific?
Which companies dominate the biomarker testing services landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization